Direct Answer
Johnson & Johnson (JNJ) listed on the New York Stock Exchange on September 24, 1944, at an initial price of approximately $37.50 per share on a split-adjusted basis. The company has completed six 2-for-1 stock splits since then (in 1981, 1989, 1992, 1996, 1999, and 2001), producing a cumulative split factor of 64x. JNJ is a Dividend King with 62 consecutive years of annual dividend increases as of 2024, paying $1.24 per quarter ($4.96 annualized) in fiscal year 2024. Johnson & Johnson joined the Dow Jones Industrial Average on March 17, 1997, replacing Bethlehem Steel, and remains a current Dow 30 constituent.
NYSE listing and early history
Johnson & Johnson listed on the New York Stock Exchange on September 24, 1944, under the ticker symbol JNJ. Founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, the company had operated as a private entity for nearly six decades before its public offering. The initial price was approximately $37.50 per share on a split-adjusted basis, reflecting the company's established position in surgical dressings, adhesive bandages, and consumer health products.
The 1944 NYSE listing gave J&J access to public capital markets at a time when it was expanding beyond its consumer health origins into pharmaceuticals and medical devices. This transition, accelerated over subsequent decades, would ultimately define the company's investment character as a diversified healthcare business.
| Listing Detail | Value |
|---|---|
| Listing Date | September 24, 1944 |
| Exchange | New York Stock Exchange (NYSE) |
| Ticker | JNJ |
| Initial Price (split-adjusted) | approximately $37.50 per share |
| Founded | 1886, New Brunswick, New Jersey |
| Years private before NYSE | approximately 58 years |
Stock split history
Johnson & Johnson has completed six 2-for-1 stock splits since its 1944 NYSE listing. The cumulative split factor is 64x (2 raised to the power of 6), meaning one original share became 64 shares after all six splits. All splits were 2-for-1. The last split occurred on June 14, 2001, and no further splits have been announced since then.
| Split Number | Effective Date | Ratio |
|---|---|---|
| 1st split | June 1, 1981 | 2-for-1 |
| 2nd split | May 26, 1989 | 2-for-1 |
| 3rd split | September 4, 1992 | 2-for-1 |
| 4th split | June 13, 1996 | 2-for-1 |
| 5th split | June 3, 1999 | 2-for-1 |
| 6th split | June 14, 2001 | 2-for-1 |
The six splits occurred during J&J's decades of sustained growth, each reducing the nominal share price to keep shares accessible to a broad investor base. The cluster of splits in 1996, 1999, and 2001 reflected the strong share price appreciation of the late 1990s. Since 2001, J&J shares have not been split again. At late 2024 prices of approximately $160 per share, the nominal price remains well below the levels that historically prompted previous splits, partly because the share count has been reduced through buybacks rather than increased through splits.
Dividend history and Dividend King status
Johnson & Johnson is one of a small group of companies known as Dividend Kings: companies that have raised their annual dividend for 50 or more consecutive years. As of 2024, JNJ has increased its dividend for 62 consecutive years, making it one of the longest-tenured Dividend Kings in the S&P 500. The company initiated its dividend in 1944 at the time of its NYSE listing and has never suspended or cut the payment in over eight decades.
| Dividend Metric | Detail |
|---|---|
| Dividend initiated | 1944 (at time of NYSE listing) |
| Consecutive years of increases (as of 2024) | 62 years |
| Status | Dividend King (50+ consecutive years of increases) |
| FY2024 quarterly dividend | $1.24 per share |
| FY2024 annualized dividend | $4.96 per share |
| Dividend yield (late 2024, approx. $160/share) | approximately 3.1% |
| Total dividends paid FY2024 | approximately $11.8 billion |
| Dividend cuts or suspensions | None since 1944 |
The 62-year consecutive increase streak reflects J&J's ability to generate durable free cash flow through multiple economic cycles, patent cliffs, product liability challenges, and major business model changes including the 2023 Kenvue spinoff of its consumer health division. The dividend yield of approximately 3.1% at late 2024 prices is notably higher than Visa or Mastercard's yields, a reflection of JNJ's more modest recent price appreciation and its positioning as an income-oriented healthcare holding rather than a pure growth name.
The higher yield relative to the company's historical average is partly attributable to valuation compression related to the talc litigation overhang and investor uncertainty around Stelara biosimilar competition, which weighed on the stock in 2023 and 2024 even as the underlying business remained profitable.
Dow Jones Industrial Average membership
Johnson & Johnson was added to the Dow Jones Industrial Average on March 17, 1997, replacing Bethlehem Steel as part of concurrent component changes to the index that day. The addition recognized J&J's size and importance in the healthcare sector, which had grown substantially as a share of the U.S. economy by the late 1990s.
JNJ remains a current Dow 30 constituent and is one of the longest-tenured healthcare names in the index. As a large-cap, moderate-priced stock relative to some other Dow components, J&J carries a mid-range weight in the price-weighted Dow. In a price-weighted index, a stock's day-to-day price movement influences the index in proportion to its absolute share price, so J&J's influence on the Dow fluctuates as its share price moves relative to other components.
| Dow Detail | Value |
|---|---|
| Added to DJIA | March 17, 1997 |
| Replaced | Bethlehem Steel (concurrent changes) |
| Current Dow 30 member | Yes (as of 2026) |
| Index type | Price-weighted |
Share repurchases
Johnson & Johnson has reduced its share count significantly over time through sustained buyback programs. From approximately 3.0 billion shares outstanding around 2010, the total has declined to approximately 2.4 billion shares by 2024, a reduction of roughly 20 percent over 14 years. In fiscal year 2024, J&J repurchased approximately $5.0 billion of its own stock.
| Buyback Metric | Detail |
|---|---|
| FY2024 share repurchases | approximately $5.0 billion |
| Shares outstanding (approx. 2010) | approximately 3.0 billion |
| Shares outstanding (approx. 2024) | approximately 2.4 billion |
| Long-term reduction | approximately 20% over 14 years |
The buyback program complements the dividend as a capital return mechanism. Unlike Visa or other capital-light technology-adjacent businesses that can return large sums purely through buybacks, J&J balances buybacks against significant R&D investment requirements, manufacturing capital expenditures, and periodic large acquisitions. The $5.0 billion in FY2024 buybacks is meaningful but modest relative to the company's market capitalization, prioritizing a stable and growing dividend as the primary shareholder return vehicle.
Valuation context
Johnson & Johnson's valuation framework reflects its dual character as both a large pharmaceutical company (Innovative Medicine segment) and a medical technology company (MedTech segment) following the 2023 Kenvue spinoff of the consumer health business. Valuing J&J requires understanding which business lines drive each metric and how the pharmaceutical patent cycle affects forward earnings estimates.
| Valuation Metric | Late 2024 (approximate) |
|---|---|
| Market capitalization | approximately $375 billion to $395 billion |
| Share price reference | approximately $160 per share |
| Shares outstanding | approximately 2.4 billion |
| GAAP P/E | approximately 27x to 28x |
| Adjusted P/E | approximately 16x to 17x |
| Forward P/E (consensus FY2025) | approximately 14x to 15x |
| EV/EBITDA | approximately 15x |
Why GAAP and adjusted P/E diverge
The wide gap between J&J's GAAP P/E (approximately 27x to 28x) and adjusted P/E (approximately 16x to 17x) reflects significant charges below the operating line: litigation reserves and settlements related to talc and other product liability matters, amortization of intangible assets from acquisitions, and restructuring charges. Analysts typically use the adjusted figure to assess the underlying earning power of the pharmaceutical and MedTech businesses. Investors who rely solely on GAAP earnings per share will overstate the earnings drag from non-cash and one-time items, while those who rely solely on adjusted figures may underweight the real cash cost of litigation and acquisition goodwill.
Pharmaceutical segment valuation considerations
The Innovative Medicine segment generates the majority of J&J's operating profit and is valued primarily on pipeline depth and near-term loss of exclusivity exposure. The immunology drug Stelara faced biosimilar competition beginning in 2023, creating near-term revenue headwinds that weighed on JNJ shares in 2023 and 2024. Investors model the offset from pipeline drugs in oncology, immunology, and neuroscience against the Stelara erosion to determine whether overall segment earnings grow or contract in the 2024 to 2027 period.
MedTech segment and sum-of-the-parts
The MedTech segment, covering surgical robotics, electrophysiology, cardiovascular devices, and orthopedics, is often valued using EV/revenue or EV/EBITDA multiples benchmarked to pure-play medical device peers such as Medtronic, Stryker, and Boston Scientific. A sum-of-the-parts analysis applies a pharmaceutical peer multiple to Innovative Medicine earnings and a device peer multiple to MedTech earnings. This approach typically produces a different implied value than applying a single blended multiple to consolidated earnings, and analysts disagree on which methodology better reflects underlying business quality.
Talc litigation and valuation discount
The talc litigation overhang has suppressed JNJ's valuation multiples relative to pharmaceutical peers for several years. The company has pursued legal resolution through its subsidiary structure, but ongoing uncertainty about the ultimate cost of settlements created a meaningful valuation discount in 2023 and 2024 that partially explains the stock's underperformance relative to the S&P 500 during that period. Investors who believe the litigation liability is quantifiable and manageable may view the discount as an opportunity; those who remain uncertain about the total liability may treat it as a persistent risk.
More on Johnson & Johnson
Frequently Asked Questions
When did Johnson & Johnson list on the stock market?
Johnson & Johnson listed on the New York Stock Exchange on September 24, 1944, under the ticker symbol JNJ. The initial price was approximately $37.50 per share on a split-adjusted basis. The company had been founded in 1886 and operated as a private company for nearly six decades before its NYSE listing.
How many times has Johnson & Johnson split its stock?
Johnson & Johnson has completed six stock splits since its 1944 listing, all 2-for-1: June 1, 1981; May 26, 1989; September 4, 1992; June 13, 1996; June 3, 1999; and June 14, 2001. The cumulative split factor is 64x (2 to the power of 6), meaning one original share became 64 shares over time.
Is Johnson & Johnson a Dividend King?
Yes. Johnson & Johnson is a Dividend King, having increased its annual dividend for 62 consecutive years as of 2024. The quarterly dividend in fiscal year 2024 was $1.24 per share ($4.96 annualized). JNJ first initiated a dividend at the time of its 1944 IPO and has never suspended or cut the payment since.
When did Johnson & Johnson join the Dow Jones Industrial Average?
Johnson & Johnson was added to the Dow Jones Industrial Average on March 17, 1997, replacing Bethlehem Steel (as part of concurrent Dow component changes that day). JNJ remains a current Dow 30 constituent and is one of the longest-tenured healthcare names in the index.